TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6419519
Drug: Piribedil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (all doses)
Study: 31093929
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 338 administered 0 min before meal
Study: 31093929
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 338 administered 30 min before meal
Study: 31093929
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 338 administered 60 min before meal
Study: 31093929
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin 338 administered 360 min before meal
Study: 29772035
Drug: MDI implants
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI implants (3M ESPE)
Study: 29772035
Drug: SlimLine implants
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SlimLine implants (Dentium)
Study: 10320236
Drug: Aortic homograft
Normalized name: chloroxylenol / hydrocortisone / pramoxine hydrochloride Otic Solution [Cortic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic homograft preserved in antibiotic solution at 4 degrees C
Study: 8708151
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intralesional IFN alfa-2a and 2b
Study: 19161542
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU daily of vitamin D(2) for mothers
Study: 19161542
Drug: 60,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60,000 IU monthly of vitamin D(2) for mothers
Study: 19161542
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU daily of vitamin D(2) for infants
Study: 17450047
Drug: Fast/once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast/once daily titration (1.2 mg/kg/day over 3 days)
Study: 17450047
Drug: Slow/twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow/twice daily titration (1.2 mg/kg/day over at least 2 weeks)
Study: 17450047
Drug: Slow/twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow/twice daily titration
Study: 15016780
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy with 400 mcg buserelin acetate daily followed by 6 mg of oral estradiol valerate starting on menstrual day 1
Study: 15016780
Drug: No GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GnRH agonist therapy, starting 6 mg of oral estradiol valerate on day 1 of bleeding
Study: 11206232
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg twice daily
Study: 11206232
Drug: Formoterol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (both doses)
Study: 9537731
Drug: Gauze drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gauze drain impregnated with chlortetracycline ointment
Study: 9537731
Drug: No drain
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drain treatment (control)
Study: 8079448
Drug: Low-dose IVIgG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IVIgG (85.7 +/- 11.6 mg/kg by ultrasound‐estimated fetal weight)
Study: 8079448
Drug: Low-dose IVIgG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IVIgG
Study: 2590616
Drug: Intranasal metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal metoclopramide (5 mg in 0.5 ml sterile water)
Study: 2590616
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route (implied control)
Study: 241307
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily administration of phenothiazine medication
Study: 241307
Drug: Multiple administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple administration schedule of phenothiazine medication
Study: 31329855
Drug: AKCEA-APOCIII-LRx 10
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 10 mg
Study: 31329855
Drug: AKCEA-APOCIII-LRx 30
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 30 mg
Study: 31329855
Drug: AKCEA-APOCIII-LRx 60
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 60 mg
Study: 31329855
Drug: AKCEA-APOCIII-LRx 90
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 90 mg
Study: 31329855
Drug: AKCEA-APOCIII-LRx 120
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 120 mg
Study: 31329855
Drug: AKCEA-APOCIII-LRx 15
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 15 mg weekly for 6 weeks
Study: 31329855
Drug: AKCEA-APOCIII-LRx 30
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 30 mg weekly for 6 weeks
Study: 31329855
Drug: AKCEA-APOCIII-LRx 60
Normalized name: AKCEA-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKCEA-APOCIII-LRx 60 mg every 4 weeks for 3 months
Study: 21159452
Drug: MMT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMT with weekly individual BDRC (n=20)
Study: 16640847
Drug: DTPw-HB/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB/Hib vaccine (5 microg of PRP), given as a single injection
Study: 16640847
Drug: Licensed DTPw-HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed DTPw-HB (Tritanrix) and Hib (Hiberix) vaccines, given as simultaneous concomitant injections
Study: 16640847
Drug: DTPw-HB/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB/Hib vaccine
Study: 16640847
Drug: Licensed DTPw-HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed DTPw-HB and Hib vaccines
Study: 12969103
Drug: Intrathecal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal midazolam (1 mg) added to 3 ml of 0.5% hyperbaric bupivacaine
Study: 12969103
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 ml of 0.5% hyperbaric bupivacaine alone
Study: 29077615
Drug: Epinephrine 200
Normalized name: Cocaine (as cocaine hydrochloride) 50 mg/mL and epinephrine 200 microgram/mL eye solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 200 µg (high-dose group)
Study: 29077615
Drug: Epinephrine 100
Normalized name: Epinephrine 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine 100 µg (low-dose group)
Study: 27837602
Drug: Multicomponent behavioral
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent behavioral intervention administered by lay health workers (5 weekly 90-minute sessions)
Study: 20486914
Drug: Dual immunosuppressive
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual immunosuppressive therapy
Study: 20486914
Drug: Lower blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower blood concentrations of calcineurin inhibitors
Study: 20486914
Drug: Valganciclovir/ganciclovir therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir/ganciclovir therapy with lower total intensity of immunosuppressive therapy
Study: 20486914
Drug: Mycophenolate and
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate and tacrolimus therapy
Study: 11916787
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same formulation without lidocaine) via iontophoresis
Study: 10216810
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for 10 weeks
Study: 10216810
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily for 2 weeks, with the option to increase to 10 mg once daily if diastolic blood pressure exceeded 90 mmHg
Study: 2223679
Drug: Betamethasone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (1.5 mg orally per day from day 259 to day 273, then 1 mg until delivery)
Study: 30608872
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea (8000 mg·day‐1)
Study: 29285889
Drug: Topical liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposome incorporated clove oil 45%
Study: 29285889
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution (control)
Study: 22169248
Drug: Davunetide (AL-108)
Normalized name: Al
DrugBank: Davunetide (DB12613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davunetide (AL-108) 5 mg
Study: 22169248
Drug: Davunetide (AL-108)
Normalized name: Al
DrugBank: Davunetide (DB12613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davunetide (AL-108) 30 mg
Study: 11889309
Drug: Inspired gas
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspired gas conditions of 30 degrees C, 30 mg/L; 34 degrees C, 38 mg/L; 37 degrees C, 44 mg/L; and 40 degrees C, 50 mg/L
Study: 10080336
Drug: IFN-alpha (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha (1 x 10(6) IU per dose)
Study: 10080336
Drug: 5-FU (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (5 mg per dose)
Study: 22322513
Drug: Scaling, root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling, root planning, and systemic administration of doxycycline
Study: 19804842
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (PPI, amoxicillin followed by PPI, clarithromycin, and imidazole agent)
Study: 19804842
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (PPI, amoxicillin, clarithromycin, and imidazole agent)
Study: 17626987
Drug: Crystacide (hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystacide (hydrogen peroxide cream) applied onto the skin for 10 days
Study: 12395437
Drug: Renal protection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal protection with mannitol (0.3 g/kg) before aortic cross-clamping (ACC) and furosemide (20-40 mg) or dopamine (1-3 micrograms/kg/min) until the end of surgery.
Study: 10091344
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (0.2%)
Study: 10091344
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (500 mg/12 h)
Study: 10091344
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin plus 0.2% topical solution
Study: 10091344
Drug: Topical polymyxin
Normalized name: polymyxin B Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical polymyxin and neomycin
Study: 7748985
Drug: Loxiglumide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (10 mg/kg ideal weight/h)
Study: 2148224
Drug: isradipine 1
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 1 mg i.v. (5 min)
Study: 2148224
Drug: isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 5 mg solution
Study: 2148224
Drug: isradipine 5
Normalized name: isradipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 5 mg tablet
Study: 2148224
Drug: isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 10 mg sustained release
Study: 26022239
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no high-dose cytarabine)
Study: 21222604
Drug: EHT0202 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHT0202 (40 or 80 mg bid)
Study: 19573497
Drug: Dextroamphetamine 30
Normalized name: dextroamphetamine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 30 mg/d
Study: 19573497
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg/d
Study: 9398875
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg bid plus amoxicillin, 1 gm tid
Study: 9398875
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg tid plus amoxicillin, 1 gm tid
Study: 9398875
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg tid alone
Study: 9398875
Drug: Amoxicillin, 1
Normalized name: Amoxicillin, 125 mg oral tablet, chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, 1 gm tid alone
Study: 9398875
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg bid plus amoxicillin
Study: 9398875
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg tid plus amoxicillin
Study: 1572111
Drug: Probenecid (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (1000 mg/d)
Study: 1572111
Drug: Probenecid (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (2000 mg/d)
Study: 1572111
Drug: Furosemide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.5 mg/kg intravenously)
Study: 4048886
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (0.1 mg/kg/min)
Study: 28207540
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg enantone
Study: 21730029
Drug: Postexercise protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postexercise protein feeding (PTN: 0.4, 1.2, 0.2 g/kg protein, carbohydrate, and fat respectively)
Study: 21730029
Drug: Isocaloric carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric carbohydrate and fat (CON: 1.6, 0.2 g/kg)
Study: 30102667
Drug: V-pattern injection
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-pattern injection (group 1)
Study: 30102667
Drug: Middle horizontal
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle horizontal pattern injection (group 2)
Study: 30102667
Drug: High horizontal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High horizontal pattern injection (group 3)
Study: 17288230
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) with significant restriction of the number of cigarettes smoked per day
Study: 15248628
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg kg(‐1) min(‐1)
Study: 8956395
Drug: Lidocaine-clonidine retrobulbar
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine-clonidine retrobulbar block (3-4 mL of 2% lidocaine with clonidine 2 micrograms/kg)
Study: 8956395
Drug: Lidocaine retrobulbar
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine retrobulbar block (3-4 mL of 2% lidocaine with 1 mL saline)
Study: 31647836
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg twice daily (BID) for fifteen days
Study: 31647836
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg once daily (QD) added on day six
Study: 20145562
Drug: Cystine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine (700 mg) and theanine (280 mg) supplementation
Study: 20145562
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose 950 mg and glutamate 30 mg)
Study: 19056532
Drug: Infliximab (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (0.8 mg/ml)
Study: 16837737
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg daily for 15 days plus serratiopeptidase 10 mg daily for 30 days
Study: 10664830
Drug: Ketamine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (intravenous bolus 0.26 mg/kg followed by infusion of 0.65 mg/kg/hour)
Study: 8403806
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose ingestion (75 g) in hypertensive patients
Study: 8403806
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose ingestion (75 g) with potassium chloride supplementation in hypertensive patients
Study: 8403806
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose ingestion (75 g) in normotensive control subjects
Study: 22425218
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticoagulants (NAs)
Study: 22425218
Drug: Rivaroxaban (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (40 mg QD)
Study: 10416732
Drug: Cognitive remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive remediation therapy (individual daily sessions of 1 hour for up to 3 months)
Study: 10416732
Drug: Intensive occupational
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive occupational therapy (control group)
Study: 7569830
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol replacement therapy plus norethisterone acetate 1 mg per day, oral, cyclically for 12 days monthly
Study: 2341828
Drug: ESKIMO-3 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESKIMO-3 (15 ml daily for 6 months)
Study: 2341828
Drug: ESKIMO-3 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESKIMO-3 (30 ml daily for 4 weeks)
Study: 6376030
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with energy and carbohydrate restriction
Study: 19996813
Drug: ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac tromethamine 0.4% (one drop twice a day for 2 weeks)
Study: 19996813
Drug: artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artificial tear solution (placebo, used for 2 weeks)
Study: 18004596
Drug: Tolterodine 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1-2 mg
Study: 18004596
Drug: Imipramine 25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 25-50 mg
Study: 10784228
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg nateglinide (single oral dose, given 20 min prior to IGTT)
Study: 8769510
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine hydrochloride infusion (0.5 g/kg for 30 minutes)
Study: 3902588
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg at lunch, 400 mg at bedtime)
Study: 31244692
Drug: Robin (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robin (16 weekly individual sessions + a minimum of 4 family sessions)
Study: 31244692
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (active control group)
Study: 22851072
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion with TCI vein pump (Group B)
Study: 22851072
Drug: Remifentanil vein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil vein infusion with PCA pump (Group C)
Study: 10649262
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (oral cancer screening)
Study: 1535816
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms HBs antigen vaccine
Study: 1535816
Drug: Other hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hepatitis B vaccine
Study: 6150660
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg ketamine intravenously
Study: 6150660
Drug: 5.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/kg thiopental intravenously
Study: 23569301
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6)
Study: 23569301
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6) with resection of liver metastases
Study: 23569301
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone without resection
Study: 21860843
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug (seven doses)